Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Hemophilia A (coagulation factor VIII deficiency) is a debilitating genetic disorder that is primarily treated with intravenous replacement therapy. Despite variety of FVIII protein formulations available, the risk of developing anti-dug antibodies (“inhibitors”) remains. Overall, 20-30% of patients with severe disease develop inhibitors. Current clinical Immune Tolerance Induction (ITI) protocols to eliminate inhibitors are not effective in all patients, and there are no prophylactic protocols to prevent the immune response. New experimental therapies, such as gene and cell therapies, show promising results in pre-clinical studies in animal models of hemophilia. Examples include hepatic gene transfer with viral vectors, genetically engineered regulatory T cells (Treg), in vivo Treg induction using immune modulatory drugs, and maternal antigen transfer. Furthermore, an oral tolerance protocol is being developed based on transgenic lettuce plants, which suppressed inhibitor formation in hemophilic mice and dogs. Hopefully, some of these innovative approaches will reduce the risk of and/or more effectively eliminate inhibitor formation in future treatment of hemophilia A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“Currently, hemophilia A is treated with an intravenous infusion of plasma-derived or recombinant clotting FVIII concentrates, which can be on demand or prophylactic (8, 9).”
BackgroundLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273 · cited 1×
“A first successful gene therapy for hemophilia B, utilizing in vivo gene transfer to the liver with an AAV vector, was documented in recent years (74).”
BackgroundGlobal Manufacturing of CAR T Cell Therapy
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765 · cited 1×
“Antigen recognition and cell signaling by CAR expressing T lymphocytes are therefore independent of APCs and is not MHC restricted (59, 60).”
BackgroundClinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637 · cited 1×
“Antigen recognition and cell signaling by CAR expressing T lymphocytes are therefore independent of APCs and is not MHC restricted (59, 60).”
BackgroundInduction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466 · cited 3×
“Studies in Fas-deficient mice suggested that Treg induction and T-cell deletion were both required for robust tolerance induction (79, 84).”
BackgroundSelf-citationPolymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408686111 · Cited by 441 · cited 1×
“Transient co-administration of FVIII and rapamycin-nanoparticles similarly induced lasting tolerance in the hemophilia A mouse model and also diminished preexisting inhibitors (46, 47).”
BackgroundMingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254
A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Brown, B. D., Cantore, A., Annoni, A., Sergi, L. S., Lombardo, A., Della Valle, P., D'Angelo, A., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2007-03-078493 · Cited by 252
Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom
Hay, C. R. M., Palmer, B., Chalmers, E., Liesner, R., Maclean, R., Rangarajan, S., Williams, M., Collins, P. W., & on behalf of United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) (2011) · Blood · doi:10.1182/blood-2010-09-308668 · Cited by 174
Liver-directed lentiviral gene therapy in a dog model of hemophilia B
Cantore, A., Ranzani, M., Bartholomae, C. C., Volpin, M., Valle, P. D., Sanvito, F., Sergi, L. S., Gallina, P., Benedicenti, F., Bellinger, D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1405 · Cited by 158
Finn, J. D., Ozelo, M. C., Sabatino, D. E., Franck, H. W. G., Merricks, E. P., Crudele, J. M., Zhou, S., Kazazian, H. H., Lillicrap, D., Nichols, T. C., et al. (2010) · Blood · doi:10.1182/blood-2010-06-288001 · Cited by 157
Yoon, J., Schmidt, A., Zhang, A.-H., Königs, C., Kim, Y. C., & Scott, D. W. (2017) · Blood · doi:10.1182/blood-2016-07-727834 · Cited by 150
Mátrai, J., Cantore, A., Bartholomae, C. C., Annoni, A., Wang, W., Acosta-Sanchez, A., Samara-Kuko, E., De Waele, L., Ma, L., Genovese, P., et al. (2011) · Hepatology · doi:10.1002/hep.24230 · Cited by 139 · cited 1×
“Improved safety profiles have been reported with the development of hepatocyte-targeted, integrase-defective LV, which resulted in a sustained expression of FIX, tolerant to neutralizing antibody induction in hemophilia B mice, and without the risk of insertional mutagenesis (96).”
BackgroundInduction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer
Dobrzynski, E., Mingozzi, F., Liu, Y.-L., Bendo, E., Cao, O., Wang, L., & Herzog, R. W. (2004) · Blood · doi:10.1182/blood-2004-03-0847 · Cited by 135
Self-citationDu, L. M., Nurden, P., Nurden, A. T., Nichols, T. C., Bellinger, D. A., Jensen, E. S., Haberichter, S. L., Merricks, E., Raymer, R. A., Fang, J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3773 · Cited by 119 · cited 1×
“Similarly, LV-modified autologous canine megakaryocytes (precursors of platelets) expressing FVIII in α-granules prevented bleeding episodes in hemophilia A dogs (137).”
BackgroundEffective gene therapy for haemophilic mice with pathogenic factor IX antibodies
Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., & Herzog, R. W. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302859 · Cited by 116
Self-citationDobrzynski, E., Fitzgerald, J. C., Cao, O., Mingozzi, F., Wang, L., & Herzog, R. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508685103 · Cited by 105
Self-citationLange, A. M., Altynova, E. S., Nguyen, G. N., & Sabatino, D. E. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.64 · Cited by 78 · cited 1×
“Improvements such as codon optimization of the F8 gene and deletion of the B domain have, however, resulted in only a mild activation of the unfolded protein response in mice, which did not impact liver pathology or FVIII immunogenicity (91, 92).”
BackgroundHoffman, B. E., Martino, A. T., Sack, B. K., Cao, O., Liao, G., Terhorst, C., & Herzog, R. W. (2011) · Molecular Therapy · doi:10.1038/mt.2011.33 · Cited by 72 · cited 1×
“Intrahepatic IL-10 expression further enforced suppression of CD8+ T cells, without affecting antibody levels, while TGF-β expression was required for both Treg induction and to control transgene antibody formation in AAV-hFIX transduced hepatocytes (86).”
BackgroundSelf-citationDevelopment of gene transfer for induction of antigen-specific tolerance
Sack, B. K., Herzog, R. W., Terhorst, C., & Markusic, D. M. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.13 · Cited by 70 · cited 1×
“From an immunological point of view, hepatic gene transfer has the major advantage that transgene expression in the hepatic environment can induce immune tolerance (78) (Figure 1).”
BackgroundSelf-citationBiswas, M., Sarkar, D., Kumar, S. R. P., Nayak, S., Rogers, G. L., Markusic, D. M., Liao, G., Terhorst, C., & Herzog, R. W. (2015) · Blood · doi:10.1182/blood-2014-09-599266 · Cited by 70
Self-citationNAYAK, S., CAO, O., HOFFMAN, B. E., COOPER, M., ZHOU, S., ATKINSON, M. A., & HERZOG, R. W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03548.x · Cited by 66 · cited 3×
“The tolerogenic effect of rapamycin can be further enhanced by addition of cytokines such as IL-10 or Flt3L (44, 45, 48).”
BackgroundSelf-citationPotential for cellular stress response to hepatic factor VIII expression from AAV vector
Zolotukhin, I., Markusic, D. M., Palaschak, B., Hoffman, B. E., Srikanthan, M. A., & Herzog, R. W. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.63 · Cited by 65 · cited 1×
“Improvements such as codon optimization of the F8 gene and deletion of the B domain have, however, resulted in only a mild activation of the unfolded protein response in mice, which did not impact liver pathology or FVIII immunogenicity (91, 92).”
BackgroundSelf-citationZhang, A.-H., Rossi, R. J., Yoon, J., Wang, H., & Scott, D. W. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2015.11.004 · Cited by 65
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
Self-citationHu, C., & Lipshutz, G. S. (2012) · Gene Therapy · doi:10.1038/gt.2011.200 · Cited by 48 · cited 1×
“Mice also remained tolerant to a subsequent FVIII challenge in adjuvant, performed 8 weeks after gene transfer (135).”
Background
Cited by
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Parvathaneni, K., & Scott, D. W. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018018556 · Cited by 56
Fuchs, S. P., Martinez-Navio, J. M., Rakasz, E. G., Gao, G., & Desrosiers, R. C. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.010 · Cited by 32
Herzog, R. W., Kuteyeva, V., Saboungi, R., Terhorst, C., & Biswas, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00274 · Cited by 24
Self-citation
Metadata
- Authors
- Sherman, A., Biswas, M., & Herzog, R. W.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-11-24
- Volume
- 8
- Pages
- 1604-1604
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2767648877
- Cited by
- 33
- References
- 26
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.